Lab
My Genius Lab LLC
My Genius Lab LLC was paid $1.47M by Medicaid between Jun 2021 and Dec 2024, across 45 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 39% of everything it billed.
33Billing provider infoMY GENIUS LAB LLC
LAS VEGAS, NV 89118
LAS VEGAS, NV 89118
33aNPI1407474190assigned 07/08/2020
33bProvider typeClinical Medical Laboratory
28Total paid$1.47M
24GClaims89,490
24DCodes billed45
24AFirst – last monthJun 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Nevada
Rank by total paid#11 of 31
Median peer was paid$269K
This provider vs. median5.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 19,297 | $28K | |
| 2022 | 29,262 | $366K | |
| 2023 | 28,421 | $728K | |
| 2024incomplete | 12,510 | $345K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 39% | 8,104 | 5,330 | $573K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 26% | 14,809 | 4,939 | $378K |
| 87640 | 3.9% | 6,873 | 5,290 | $57K | |
| 87481 | 3.5% | 4,580 | 3,186 | $51K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.1% | 2,293 | 1,670 | $46K |
| 87653 | 2.8% | 3,707 | 3,120 | $41K | |
| 87500 | 2.2% | 3,218 | 2,722 | $32K | |
| 87641 | 2.1% | 3,139 | 2,651 | $31K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.8% | 13,245 | 4,744 | $26K |
| 87581 | 1.6% | 3,394 | 2,762 | $23K | |
| 87486 | 1.6% | 3,388 | 2,759 | $23K | |
| 87541 | 1.6% | 3,341 | 2,748 | $23K |
33 more codes
| 87496 | 1.6% | 1,377 | $23K | |
| 87498 | 1.5% | 1,376 | $23K | |
| 87532 | 1.5% | 1,270 | $22K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 1,167 | $19K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 891 | $16K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 443 | $12K |
| 87529 | <1% | 275 | $6K | |
| 87516 | <1% | 172 | $4K | |
| 87521 | Neg quan hep c or qual rna | <1% | 172 | $4K |
| 87538 | <1% | 172 | $4K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 113 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 171 | $3K |
| 87535 | <1% | 171 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 171 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 165 | $3K |
| 87563 | <1% | 275 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,602 | $3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 18 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,855 | $1K |
| 87511 | <1% | 57 | $861.84 | |
| 87631 | <1% | 3,164 | $842.37 | |
| 80061 | Lipid panel | <1% | 104 | $475.28 |
| 87551 | <1% | 30 | $454.86 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 56 | $320.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 100 | $304.52 |
| 80053 | Comprehensive metabolic panel | <1% | 114 | $273.98 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 107 | $185.85 |
| 80050 | General health panel | <1% | 25 | $145.86 |
| 87561 | <1% | 84 | $135.06 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 52 | $91.76 |
| 84439 | <1% | 54 | $86.10 | |
| 82607 | <1% | 23 | $10.28 | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 0% | 573 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVARDAPETYAN, ARTYOM (OWNER/MANAGING MEMBER)